Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present corporate updates at two upcoming investor conferences in
September:
- 2018 Wells Fargo Healthcare Conference on Thursday, September 6, 2018 at 1:55 p.m. ET at the Westin
Copley Place in Boston.
- 16th Annual Morgan Stanley Global Healthcare Conference on Thursday, September 13, 2018 at
11:10 a.m. ET at the Grand Hyatt New York.
A live webcast of Ironwood’s presentations will be accessible through the Investors section of the company’s website at
www.ironwoodpharma.com. To access the webcasts, please log on to the Ironwood website approximately 15 minutes prior to the
start time to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on
Ironwood’s website for 14 days following the conference.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ:IRWD) is a commercial biotechnology company focused on creating medicines that make a
difference for patients, building value for our fellow shareholders, and empowering our passionate team. We are commercializing two
innovative primary care products: linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome
with constipation (IBS‐C) or chronic idiopathic constipation (CIC), and lesinurad, which is approved for the treatment of
hyperuricemia associated with gout in patients who have not achieved target serum uric acid (sUA) levels with a medically
appropriate daily dose of a xanthine oxidase inhibitor (XOI) alone. We are also advancing a pipeline of innovative product
candidates in areas of significant unmet need, including uncontrolled gastroesophageal reflux disease, diabetic nephropathy, heart
failure with preserved ejection fraction, achalasia and sickle cell disease. Ironwood was founded in 1998 and is headquartered in
Cambridge, Mass. For more information, please visit
www.ironwoodpharma.com or
www.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both these
locations.
Investor and Media Relations
Ironwood Pharmaceuticals, Inc.
Meredith Kaya, 617-374-5082
Vice President, Investor Relations and Corporate Communications
mkaya@ironwoodpharma.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180828005576/en/